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Yes. Growing evidence demonstrates that the human papillomavirus (HPV) DNA test is more sensitive than the Papanicolaou (Pap) test, with a better negative predictive value-ie, women who have negative test results can be more certain that they are truly free of cervical cancer. [1] [2] [3] On April 24, 2014, the US Food and Drug Administration (FDA) approved the Cobas HPV test developed by Roche for use as the fi rst-line screening test for cervical cancer in women age 25 and older. 4 The approval follows the unanimous recommendation from an independent panel of experts, Compared with Pap testing alone, cotesting offers improved detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and the ability to safely extend the screening interval to every 5 years in women who have negative results on both tests. It is an effective screening strategy and remains the standard of care today.
However, this strategy is not perfect and presents several problems for clinicians. The results of the two tests often confl ict-the results of the Pap test might be positive while those of the HPV test are negative, or vice versa. Integrating the results of cotesting into triaging can be confusing and complicated. In addition, performing two tests on all women increases the cost of care. And furthermore, the cotesting strategy increases the number of women who require immediate or short-term follow-up, 1,2,10-12 such as colposcopy, which is unnecessary for many.
■ THE HPV TEST DETECTS 14 HIGH-RISK GENOTYPES
The FDA-approved HPV test detects 14 highrisk genotypes. The results for 12 of these are pooled and reported collectively as either positive or negative, while the other two- • HPV testing by itself performed better than Pap-HPV cotesting, with positive predictive values of 12.25% vs 11.04% and negative predictive values of 99.58% vs 99.52%. For women whose results were negative for HPV 16 and 18 but positive for the 12-genotype pooled panel, the sample was automatically submitted for cytologic (Pap) testing. Reserving Pap testing for samples in this category improved the specifi city of the test and resulted in fewer colposcopy referrals. The ATHENA researchers found that 11.4% of the participants who tested positive for either HPV 16 or 18 had CIN2+. 13 Other large cohort studies 14, 15 also showed that the shortterm risk of developing CIN3+ reached 10% over 1 to 5 years in women who tested positive for HPV 16 or 18.
The proposed algorithm for screening (FIGURE 1) takes advantage of the superior sensitivity of the HPV test, the built-in risk stratification of HPV 16 [7] [8] [9] However, FDA approval of the new indication of the HPV DNA test as a stand-alone fi rst-line screening test is an important milestone. It heralds the shifting of the practice paradigm from morphologically based Pap testing to molecular testing in cervical cancer screening.
The ACS and ASCCP have announced that they are reviewing the evidence and may issue updated guidelines for clinicians in the near future. 16, 17 We anticipate that other organizations may take similar steps. As primary care physicians, we need to stay tuned and follow the most up-to-date evidence-based practice guidelines to provide the best care for our patients.
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